Previously published literature has further confirmed that HDAC inhibitors can inhibit the malignant features of cancer cells by inducing autophagy; meanwhile, IRF1 is also known to suppress the growth of human hepatocellular carcinoma cells by inducing autophagy [34, 35]. Here, HDAC9 is linked to hepatocellular carcinoma.